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Objectives: It is estimated that 30% of psoriasis (PSO) patients also develops pso-
riatic arthritis (PSA). This potential disease evolution brings along new symptoms 
such as swollen and painful joints and mobility problems. Since both diseases are 
potentially degenerative, the aim of this study was to measure which group of 
patients (PSO or PSA) is willing to pay most out of pocket to avoid their health related 
quality of life (HRQoL) to worsen. MethOds: 395 US patients diagnosed with either 
psoriasis (n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of 
a broader survey of treatment of PSO/PSA. The questionnaire included the EQ-5D-5L 
instrument and accompanying VAS. Patients were additionally asked to indicate by 
reference to the EQ-5D VAS scale the amount of money per month they would be 
willing to pay for treatments that would prevent a decline in HRQoL by 10 points. 
Price sensitivity curves were created by means of linear regression analysis that 
predict the proportion of patients willing to pay a certain amount of $ out of pocket 
per month. Results: For both PSO (R² = 0,82) and PSA (R² = 0,86) monthly cost out of 
pocket (x-variable) was a good predictor of the proportion of patients that is willing 
to pay a certain amount out of pocket per month (y-variable). Regression models 
look as follows. For PSO: y = 0,77e-0,005x for PSA: y = 0,86e-0,007x. To give a specific 
example 42% of the PSA patients is willing to pay $100 per month out of pocket 
whereas this is 47% among PSO patients. cOnclusiOns: PSO patients are prepared 
to pay more out of pocket on a monthly basis to avoid their HRQoL to worsen than 
PSA patients. Further research is required to understand what drives this difference.
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Objectives: To report the long-term effect of certolizumab pegol (CZP) on work-
place and household productivity up to 96 weeks (wks) in patients with axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS, meeting modi-
fied New York criteria) and non-radiographic axSpA (nr-axSpA). MethOds: The 
ongoing RAPID-axSpA trial (NCT01087762), is double-blind and PBO-controlled to 
Wk24, dose-blind to Wk48 and open-label to Wk204. Patients had active axSpA, 
according to ASAS criteria, including AS and nr-axSpA patients. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients enter-
ing dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W 
or CZP 400mg Q4W after Wk24 or, for non-responders, after Wk16. The validated 
arthritis-specific Work Productivity Survey (WPS; administered Q4W) assessed the 
impact of axSpA on workplace and household productivity. WPS responses (LOCF 
imputation) in patients originally randomized to CZP are summarized descriptively 
over 96 wks. Results: 325 patients were randomized, of whom 218 received CZP 
(200mg Q2W or 400mg Q4W) from Wk0. Of patients randomized to CZP at baseline 
(BL), 93% completed Wk24, 88% Wk48 and 80% Wk96. At BL, 72% of CZP patients 
were employed outside of the home. Employed CZP patients reported reductions 
in workplace absenteeism and presenteeism to Wk24, with continued improve-
ments to Wk96 (BL: mean 1.8 days missed/month, mean 5.2 days with reduced 
productivity/month vs Wk96: mean 0.6 days missed/month, mean 1.4 days with 
reduced productivity/month). CZP patients also reported continued improvements 
in household productivity and social participation to Wk96 in both dose regimens, 
and similar improvements were observed in AS and nr-axSpA. cOnclusiOns: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities were continued to Wk96 in axSpA, 
AS and nr-axSpA patients.
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Objectives: To examine the long-term effect of certolizumab pegol (CZP) on 
workplace and household productivity up to 96 weeks (wks) in patients with active 
psoriatic arthritis (PsA). MethOds: The ongoing RAPID-PsA trial (NCT01087788) 
is double-blind and PBO-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients entering 
dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W or 
400mg Q4W after Wk24 or, for non-responders, Wk16. The validated arthritis-spe-
cific Work Productivity Survey (WPS) administered Q4W from baseline (BL), assessed 
the impact of PsA on workplace and household productivity in the randomized set. 
WPS responses (LOCF imputation) in patients originally randomized to CZP groups 
are summarized descriptively over 96 wks. Results: 409 patients were randomized, 
of whom 273 received CZP 200mg Q2W or CZP 400mg Q4W. Of patients randomized 
to CZP, 91% completed Wk24, 87% Wk48 and 80% Wk96. In employed patients in both 
CZP groups (60.8% of all CZP patients at BL), decreases in absenteeism and pres-
enteeism to Wk24 were continued up to Wk96 (BL: mean 2.0 and 1.6 days missed/
month in the CZP 200mg Q2W and 400mg Q4W groups, respectively; mean 5.2 and 
5.1 days with reduced productivity/month vs Wk96: mean 0.3 and 0.4 days missed/
month; mean 0.7 and 1.5 days with reduced productivity/month). Improvements in 
household productivity and social participation reported in both CZP groups over 
24 wks were also maintained to Wk96. cOnclusiOns: The initial improvements 
present study was to measure the functional status and quality of life in RD patients receiving 
the biologic agent golimumab in Greece MethOds: A descriptive study was conducted 
estimating the annual Quality-of-Life (QoL) improvement for 148 patients diagnosed 
with rheumatoid arthritis (RA), psoriatic arthritis (PS) and ankylosing spondylitis 
(AS). QoL was estimated with standardized questionnaires such as EQ-5D and HAQ 
questionnaire. In addition, twenty specific parameters including “general health”, 
“severity of pain”, “productivity level” etcetera wereassessed on 10-point Likert scale. 
Data was collected by doctors across the country at 3 month intervals (4 waves of 
questionnaires during the year). Results: Patients with RA reported improved QoL 
by 14%, followed by 0.67 decrease of average HAQ score. They also reported a 7.5 hours 
gain of working hours and an overall 14% gain in productivity per week. Patients with 
AS were estimated to present 30% improvement in general health condition according 
to their doctors with similar self-reported estimations. Additionally, their QoL was 
improved by 17%. Similarly, patients with PS estimated their QoL improved by 17% 
with a 6hr/week gain in working hours otherwise missed, while the average HAQ score 
fell by 0.71 Findings are in accordance with similar published studies all contributing 
to the general assumption that patients receiving biological agents experience greater 
QoL improvement compared to conservative treatment options. cOnclusiOns: 
Statistical analysis revealed significant improvement of functional status, quality of 
life, productivity gains and decrease of disease activity for those receiving Golimumab 
in Greece for all three disease groups. Amongst limitations, both number of the study 
group and follow-up period should be taken into consideration.
PMS80
Quality of life in PatientS WitH cHronic luMboSciatic SyndroMe in 
tHe Slovak rePublic
Matisakova I.1, Kamenska E.1, Mastiliakova D.2, Melus V.1, Bielik J.2, Novak I.3, Andrasova E.3
1Trencin University of Alexander Dubcek, Trencin, Slovak Republic, 2Trencin University, Trencin, 
Slovak Republic, 3Novartis Slovakia, Bratislava, Slovak Republic
Objectives: The current prevalence of Chronic Lumbosciatic Syndrome (CLSS) in 
Slovakia ranges in about 170000 cases. The CLSS has a great impact on quality 
of life (QoL) and the ability to work too. Till now in Slovakia was not realised the 
study like this. MethOds: 86 patients with CLSS were studied. The “hospital” and 
the “out-patients clinic” group had 43 vs 43 patients. The average age was 50.36 vs 
51.79 y., weight – 61.04 vs 77.95 kg, duration of illness – 5.3 vs 5.0 years, symptoms 
of illness before diagnosis – 2.27 vs 2.16 years. QoL and the ability to work was 
evaluated on the numeric scale from 0 to 10 (0 for the worst, 10 for the best) by 
patients themselves. Results: The “hospital” and the “out-patients clinic” group 
had these results: the average of hospitalisation – 1.51 vs 1.44 times, incapacity to 
work – 3.06 vs 2.90 months. QoL in the time of good health was 8.2 vs 8.04, in the 
time of diagnosis – 5.86 vs 6.74, and in the current time – 4.58 vs 3.95. The work 
ability (WA) had these results: WA in time of good health was 8.97 vs 9.04 in the 
time of diagnosis – 8.16 vs 8.13, and in the current time – 3.83 vs 3.83. The impact 
of the treatment on the QoL was 5.37 vs 6.06 and on the patients families QoL it 
was 6.16 vs 6.13. The willingness to pay for the perfect cure was 477.90 € vs 524.41 € 
per month (the average salary in Slovakia in 2013 was 824 € ). cOnclusiOns: CLSS 
has a great impact on QoL and on the WA too. There was not statistical difference 
between both “hospital and out-patient clinic” patients in the QoL and WA. Early 
diagnosis is important to effective treatment.
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Objectives: For patients with rheumatoid arthritis (RA) and inadequate response 
to traditional therapy, treatment with biologics is recommended to reduce dis-
ease progression and improve HRQol. Nevertheless, up to 30% of patients stop 
treatment on their own initiative. Aim of the study is to develop and validate an 
instrument to assess reasons for treatment discontinuation of biologics in patients 
with RA. MethOds: We conducted expert interviews with rheumatologists (n= 5) 
to develop a questioning route, which was used in 2 focus groups with a total of 
15 RA patients who dropped out therapy (phase 1). Based on these results a draft 
questionnaire was developed and pre-tested (phase 2; n= 6), resulting in the pilot 
questionnaire. In the validation phase (phase 3) the questionnaire is completed by 
approx. 200 patients, with an interim analysis planned after recruitment of half 
the sample size. Quantitative data analyses will focus on psychometric proper-
ties: missing data, floor/ceiling effects, factorial validity, distribution of properties. 
Patients are recruited at 40 German office based rheumatologists, with 5 patients 
per center. Results: The final questionnaire consists of 82 items covering socio-
demographic aspects, HRQoL, history of treatment and disease, treatment infor-
mation, expectations and satisfaction and ”reasons for discontinuation”. Piloting 
showed that HRQoL, treatment and working-life aspects have impact on treatment 
discontinuation. Particularly, information about treatment options, patient-doctor 
relationship and financial burden were addressed. The questionnaire has proven 
to be feasible in field-test. Validation phase is currently ongoing; results from the 
interim analysis will be presented. cOnclusiOns: Interviews with experts and 
patients demonstrated that treatment discontinuation is triggered by multiple rea-
sons. A targeted developed questionnaire is necessary to identify latent reasons for 
treatment discontinuation. Furthermore, an “easy-to-use” questionnaire could be 
used in daily routine to identify patients likely to withdraw treatment and need 
special patient adherence programs.This research was funded by Pfizer GmbH.
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tics. Results: 1534 eligible RA patients were assessed; Mono: 428 (28%), Combo: 
1106 (72%). Patient characteristics (Mono/Combo) included: age 51.8/51.7; female 
71%/75%; weight 68.6/68.5kg; top three comorbidities: dyslipidemia (16%/19%), depres-
sion/anxiety (9%/13%), obesity (8%/12%). Time since diagnosis: 68.6/78.2mo. Current 
line of biologic therapy: first-line 86%/75%, second-line 11%/18%, ≥ third-line 3%/6%. 
Top four biologics used across the two patient groups: etanercept (33%)/adalimumab 
(30%)/tocilizumab (9%)/certolizumab pegol (7%). Current lab values/disease severity 
measures: ESR (mm/h) 21.7/23.2; CRP (mg/l) 10.3/10.3; rheumatoid factor (positive) 
84%/87%; anti-CCP (positive) 70%/80%; current disease stage per physician judg-
ment: mild 65%/52%, moderate 32%/40%, severe 3%/8%; mean VAS 3.4/3.6; mean HAQ 
1.4/1.1; mean DAS 28 3.6/3.3; mean tender joint count 3.5/4.1; mean swollen joint 
count 2.4/2.6. cOnclusiOns: In this cohort of RA patients in Europe, the majority 
of patients on monotherapy and combination therapy had mild disease per physi-
cian judgment and were on first-line biologic therapy. Lab measures and joint counts 
indicated only slightly higher disease burden among combination therapy patients. 
The impact of specific biologic treatments on observed patterns and the need for 
therapeutic sequencing may warrant further research.
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Objectives: In Europe, biosimilars of complex molecules such as monoclonal 
antibodies have started to enter the market. In this research we aim to provide an 
understanding of the current expectations for the purchasing of these products 
as well as an overview of the tools that payers expect to employ to encourage bio-
similar use. MethOds: Qualitative survey of payers across national, regional and 
local levels in France, Germany, Italy, Spain, the UK and Netherlands. Collection and 
analysis of data on (1) current and future attitudes relative to expected biosimilar 
purchasing systems; and (2) the tools that payers expect to use to drive biosimilar 
use, assuming this is a payer goal. Results: (1) The method of biosimilar purchase 
in the short term will vary by country, with the majority of countries using tenders 
to procure these products; (2) While tenders restricting choice of product to a single 
winner will not be used extensively in the short term, these will be common across 
most countries in the future; (3) Payers will also use a number of other tools such 
as formal and informal recommendations, prescription incentives and auditing or 
prescription targets in order to encourage use of the product they have chosen; (4) 
New procurement pathways and tools are being developed to introduce biosimilars, 
as highlighted by the new biosimilar law in Italy which defines a level of discount 
at the national level. cOnclusiOns: Payer strategies should maximize savings by 
introducing less expensive biosimilars, but also must consider physician prefer-
ences, especially when influenced by potentially valid concerns about lack of data. 
In order to do this, payers are creating novel purchasing frameworks and tools, and 
while they are currently reticent to use restrictive methods to encourage use of 
biosimilars, this is expected to rapidly change in a short timeframe.
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Objectives: Despite Ontario’s universal health care system, differences exist 
in health care accessibility and quality across the province. The objective of this 
study is to assess health care resource utilization for patients with ankle sprains 
based on rurality. MethOds: Data on individuals who sought medical attention 
for ankle sprains between 2003 and 2011 in Ontario were obtained from multiple 
databases linked through the Institute for Clinical Evaluative Sciences (ICES). The 
Rurality Index of Ontario (RIO) was used to measure the rurality level of patients 
based on their population density and geographic distance to health care facili-
ties. Demographic characteristics were obtained for each of five RIO categories. 
Health care utilization (number of visits to primary care physicians, specialists and 
ambulatory care) and physician billing costs were obtained and compared among 
the RIO categories. Results: Between 2003 and 2011, the Ontario Health Insurance 
Program was billed $64 million and $36 million (2013 CAD) by specialists and gen-
eral practitioners, respectively, for the treatment of ankle sprains and dislocations. 
Approximately $116 million was spent on direct and indirect costs of emergency 
room visits for ankle sprains and dislocations. The largest proportion of rural inju-
ries occurred in the top income quintile. Patients in the most rural RIO category 
saw specialists least often and had the highest number of ambulatory care visits. 
However, specialist visits constituted higher costs when compared to GP visits. The 
highest specialist costs found were for males, elderly patients, and those who sought 
medical attention during winter. The observed statistical differences in cost of GP 
visits across RIO categories were not clinically meaningful. cOnclusiOns: The 
differences in health care utilization between RIO categories may indicate a lack 
of access to specialist care with those residing in rural areas relying on emergency 
departments for care. These results may be useful in allocating future resources to 
better serve rural patients.
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with CZP in workplace and household productivity, and social participation were 
sustained up to 96 wks in PsA patients.
MuScular-Skeletal diSorderS – Health care use & Policy Studies
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Objectives: With rising pressures on health care budgets, health technology 
assessment (HTA) agencies are increasingly scrutinizing medical devices (MDs) for 
economic benefits in addition to clinical benefits. This level of scrutiny has resulted 
in many unfavorable recommendations from agencies and only a small proportion 
of unconditionally favorable reviews. As an extension of our work reported at 2013 
ISPOR Annual Congress (Dublin, IR) this study aims to: 1) Identify key criteria cited 
by HTA agencies as major decision drivers, 2) Note common criteria among reviews 
that were positive, negative, or positive with reservations, and 3) Analyze tempo-
ral or geographic trends among decision drivers. MethOds: A review of 68 HTAs 
and reimbursement decisions of implantable MD with a variety of indications was 
conducted, focusing on decisions published from 2008-2013 identified by Quintiles’ 
HTA Watch from North America, Europe, and Australia. Clinical, economic, and other 
factors noted as pivotal to HTA and reimbursement decisions were registered and 
compared. Importantly, care was exercised to note only the criteria that triggered 
a HTA to make a favorable or unfavorable decision, as opposed to criteria that were 
only correlative. Results: Key product attributes affecting HTA decisions include 
1) sufficiency and quality of evidence, 2) cost offsets and budget impact, 3) adverse 
event profiles, and 4) comparison to existing alternatives where available. Notab 
ly, 33% of HTA decisions were negative, with many decisions citing insufficient 
evidence. Additionally, a majority of favorable HTA decisions were reserved in their 
recommendations, citing a need for additional evidence to uphold the initially 
favorable recommendation. The relative importance of economic considerations 
varied across countries. cOnclusiOns: HTA agencies’ scrutiny of sufficiency of 
evidence, among others, may significantly impact market access of medical devices. 
As such, manufacturers need careful planning to align evidence development, pric-
ing and access plans with HTA agency, payer and pricing authority requirements.
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Objectives: The process of bringing a biosimilar to market in Europe is quicker, 
easier and cheaper than developing a new biologic. As a class, rheumatoid arthritis 
(RA) has the greatest number of anti-TNF biosimilar molecules in development, with 
more expected to follow. This research was focussed on the key issues reported by 
payers and Key Opinion Leaders (KOLs) in France, Germany and Italy. MethOds: 
Supported by secondary research our study entailed conducting one hour tele-
phone interviews with influential senior payers involved in budgetary decision 
making at the national and regional level in addition to KOLs. These structured 
interviews explored how stakeholders perceived the introduction of anti-TNFs bio-
similars. Results: Payers see anti-TNF biosimilars as an opportunity to reduce the 
biologic budget but KOLs want to treat more patients within the same budget. Payers 
in Germany and France reported a greater perception of the efficacy of biosimilars 
than their counterparts in Italy. Treatment naïve patients are considered most suit-
able for anti-TNF biosimilars while automatic substitution was not favoured by 
any respondents. Nonetheless, price played a role and some KOLs stated they may 
attempt to switch existing patients who have a low risk of acute complications with 
very close monitoring. cOnclusiOns: Biosimilars may be perceived unequally 
across markets. Manufacturers are likely to require the use of differentiated value 
stories when presenting their biosimilar products to payers and KOLs, with the latter 
more inclined to perceive them as an opportunity to treat more patients with the 
same expenditure instead of reducing budgets. Manufacturers will likely struggle 
to encourage the switching of existing patients onto biosimilars without offering a 
significant discount. In France and Germany, anti-TNF RA biosimilars are currently 
generating demand that closely matches their increasing prevalence.
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Objectives: To assess the clinical characteristics of patients with RA who received 
biologic monotherapy (“Mono”) or biologic-containing combination therapy (“Combo”) 
in Europe. MethOds: A multi-country, multi-center medical chart review study of 
patients with RA was conducted in Q42012 among physicians in hospitals and pri-
vate practices to collect de-identified data on patients who were recently treated 
with a biologic as part of usual care in France/Germany/Italy/Spain/UK. Physicians 
were screened for duration of practice (3-30yrs) and patient volume (≥ 2 RA biologic 
patients/week) and recruited from a large panel to be geographically representative 
in each country. Eligible patient charts (≥ 5) were randomly selected from among 
the patients visiting each center/practice during the screening period. Physicians 
abstracted date of diagnosis, treatment patterns/dynamics, and symptomatology/
disease status. Mono and Combo patients were compared used descriptive statis-
